Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of trilobatin in preparation of medicine for treating acute liver injury

A technology of acute liver injury and trelobatin, applied in the field of pharmacy, can solve the problems of autophagy inducers to prevent and treat ALI, and achieve the effect of expanding the scope of functions

Inactive Publication Date: 2021-05-11
ZUNYI MEDICAL UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no report on using trilobatin as an autophagy inducer to prevent and treat ALI

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trilobatin in preparation of medicine for treating acute liver injury
  • Application of trilobatin in preparation of medicine for treating acute liver injury
  • Application of trilobatin in preparation of medicine for treating acute liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033]Trilobatin (TLB) protects mouse ali effect experiment

[0034]The reason for the establishment of a D-Galn / LPS: D-GalN / LPS-induced acute liver injury model is ideal, widely accepted and used as an animal model for exploration and evaluation of liver protector. Among them, GALN-induced animal liver tissue injury is similar to human acute severe hepatitis, while LPS can induce acute liver failure in GALN sensitizing mice. D-Galn / LPS can stimulate liver macrophages produce inflammation factors including tumornecrosis factor, TNF-α), interleukin, IL) -1β, IL-6, etc., resulting in inflammatory response, further damaging liver cells Even liver failure.

[0035]Effect of TLB on mouse Ali induced by D-Galn / LPS: TLB protected mouse Ali was observed using D-GalN / LPS-induced mouse Ali model. Male C57BL / 6 (body weight 18-22 g) mice were randomly divided into control group (CONTROL + TLB 40mg / kg, Model (D-Galn / LPS) + TLB 10mg / KG or TLB20 mg / kg or TLB 40 mg / kg treatment grou...

Embodiment 2

[0038]Effect of TLB on Ali Mouse Blood Clear Vallaenamase (Alt) and Valley Transuninaminase Activity (AST)

[0039]Male C57BL / 6 mice (body weight 18-22 g) were randomly divided into control group (CONTROL + TLB 40 mg / kg, model (d-galn / lps) control group, Model (D-Galn / LPS) + TLB 10mg / kg or TLB 20 mg / kg or TLB40 mg / kg treatment group, TLB dose group prophylactic administration was continuously irradiated for 7 days, and the Ali model was prepared by intraperitoneal injection D-Galn (700 mg / kg) / LPS (100 μg / kg). After 6 hours, serum, detect Alt and AST activity.

[0040]Such asfigure 2 As shown, it can be concluded by a graph, compared with normal group, the serum ALT activity in the model group is significantly increased (p<0.05); while TLB can reduce the activity of serum Alt in mice (P<0.05). From the B-graph, compared with the normal group, the serum AST activity in the model group is significantly increased (P<0.05); and TLB can reduce the activity of serum AST in mo...

Embodiment 3

[0042]Effect of TLB on inflammation factors of Ali mice

[0043]Male C57BL / 6 (body weight 18-22 g) mice were randomly divided into control group (CONTROL + TLB 40mg / kg, Model (D-Galn / LPS) control group, Model + TLB 10 mg / kg or TLB 20 mg / kg Or TLB 40 mg / kg treatment group, TLB dosage group prophylactic administration continuously for 7 days, ALI model was prepared by intraperitoneal injection D-Galn (700 mg / kg) / lps (100 μg / kg). After 6 hours, serum and test the horizontal level.

[0044]Such asimage 3 As shown, A-D is shown, compared with normal group, the blood-proof of the model group mouse blood surgery factor TNF-α, IL-1β, IL-6, and ET-1 levels are significantly increased (P<0.05); TLB can reduce the level of serum TNF-α, IL-1β, IL-6, ET-1 in mouse (P<0.05). E-F Figure, compared with normal group, the level of blood-deficitanimoni IL-4 and IL-10 in the model group is significantly reduced (P<0.05); and TLB can raise the level of serum IL-4 and IL-10 in mice (P<0.05). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of trilobatin in preparation of a medicine for treating acute liver injury, and belongs to the field of pharmacy. According to the invention, a D-GalN / LPS induced mouse acute liver injury model is constructed, trilobatin with different concentrations is given, and it is found that the trilobatin has the effect of preventing and treating D-GalN / LPS induced mouse acute liver injury and is dose-dependent. Therefore, the trilobatin can be used for preparing the medicine for treating the acute liver injury, so that a feasible new technical scheme is provided for clinical medicine. In addition, the trilobatin can be used as an autophagy inducer to induce cell autophagy. The functional range of the trilobatin is expanded, and new application of the trilobatin is provided. The implementation of the invention provides a new medicine for clinically treating acute liver injury, and develops a new direction for further industrial application of trilobatin.

Description

Technical field[0001]The present invention relates to the pharmaceutical field, and in particular, it relates to the use of trutalins in the preparation of acute liver injury drugs.Background technique[0002]Acute Liver Injury (ALI) is a variety of patients (for example, ischemia, drugs, exogenous toxicities and metabolites and infections), severe liver damage will eventually lead to not Reversible liver failure. Because of its high incidence, high mortality, seriously affecting the quality of life of patients. The ALI pathogenesis is complex and there is no ideal treatment for drugs. Therefore, there is an urgent need to clarify the mechanism of acute liver injury, find safety, effective treatment of Ali strategy or drug.[0003]The autophagy refers to a double-layer film that is detached from the non-nucleosome adhesion zone of the rough inner web, and the intracellular, and the protein is formed to form an autophagus, and the lysosome is fused to form a autophagy. The entrase body, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61K9/48A61K9/20A61K9/10A61P1/16
CPCA61K9/10A61K9/2059A61K9/4866A61K31/7034A61K47/10A61P1/16
Inventor 龚其海高健美
Owner ZUNYI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com